So now do you beleive PLX is dead money stock? Your only hope is if PFE gets out it checkbook and buys them out. Good Luck.
Here is what we know:
1) On Feb 4, PLX confirmed that it had been approached by Pfizer who expressed interest in buying the company. Apparently PLX wanted $1B, but PFE offer was lower. PLX then hired Citigroup to explore options (take over, partnership, etc.).
2) Pfizer has a well documented strategy pursuing biosimilars or follow-on biologics. In an inteview on Bloomberg, David Simmons was quoted as saying Pfizer is pursuing alliances or to buy companies that possess the technology to complete their strategy.
It is not hard to connect the dots that PLX has a unique and powerful technology that would give PFE a competitive advantage in engineering biosimilars - meaning the ability to create biologic drugs containing recombinant therapeutic proteins. It's the platform they want, not the pipeline. The 2 comapines already have a partnership. Now they just need to put egos aside, agree on a price, and shake hands. I expect something in the $8.50 to $10 range.
Sentiment: Strong Buy
PLX dead money stock unless PFE steps up to do buyout. Good luck.
Looks like everyone should have listened to Dr. Stone3 he made correct call. I did and shorted PLX. Thanks Doc.
Thank you Woodbarn. That was my impression. Genzyme's oral drug is a substrate replacement therapy which is different than enzyme replacement. The two classes of drugs are not interchangeable. I believe that oral dosing of proteins (enzymes) is unique to Protalix. A facilitated pathway to approval could be very significant. Blood levels were also achieved with oral Enbrel in animals according to Dr. Joseph Shaaltiel in his March 7th statement that trials with oral Uplyso were beginning in Israel.
Genzyme's oral gaucher's drug does have some mild cardio-vascular side-effects. It is different from Cerezyme. If PLX's oral drug is the same as the FDA approved IV drug, then PLX might be able to use the FDA 505(b)(2) NDA which references previous safety and efficacy studies. That FDA filing saves time and money.
it look like Genzyme will be ready with this oral drug before PLX. Management has a lot to loose agter they took home millions... I don't mind that they took millions I mind about pumping up hopes when they know or should have known it will take longet and harder...If you followed them closely you would have got the impression as if after FDA approval all doors will be opened... The Platform will speak to all Biotech community who will be willing to cooperate and invest.... NOTHING!!! no deal with any other drug or protein!!! NOTHING!!! so..... somebody has to pay for that.... the MOARD has to realize that something is wrong here... we are talking about somthing very big- a new platform!! where is it??? do we have indeed a new platform for various drugs? if yes why nobody put his money in this company??? the big companies are looking for new technologies.... where are they???
If the ongoing Oral agent study shows adequate serum levels (study should be completed within a few months), what type of studies are needed prior to being able to produce an oral agent to sell? The drug has already been shown to be safe and effective when given intravenously and there is a cross-over study from cerezyme to Uplyso that shows this is safe. This could be a game-changer for the Gaucher community. How long would it have to take to get "approval" of an oral agent in the USA, Israel, Brazil and possibly even Europe? Also would make it much easier to reach the 5000 or so "untreated" patients that exist throughout the world. Does Pfizer "own" 60% of the oral agent market outside of Israel?
The potential for therapeutic proteins to be given orally has much wider implications than just for Uplyso. Are any other companies close to being able to do this?
Lets hope for a Brazil deal to help provide operating revenue (along with the US and Israel) while the company pursues these other opportunities. Or maybe another Sanofi/Genzyme disaster?!?!
I don't think the company will be sold cheaply. This may be a longer term hold than we may have thought, but still tons of potential.
I agree with Nuselrami that it's tough to watch the management get rich while we sit and wait, but I guess they are doing all the work and I'm sure they have much more to gain from the company's ultimate success than we do.
when they need another company to do it for them it is becoming no so certain it will happen.... unfortunately I do not see any buyout unless the price is very low...management pumpt up expectations but in reality nothing...
it is allways amazing how they turn the things around....I dont think there was any basis for their claims about the platform and the big intrest in the Company, they knew that the road is very long and difficult but they pumpt up expectations about this "platform", this became to be missleading and not true in my view... in between they convinced the board to give them more and more options and hudge salaries... it is something that is too clear not to be true but I am still willing to give them the benefit of the doubt... lets see in the comung months... i do not see any buyout but I still think Brazil deal will be signed soon.Now I can understand why frost went out, why Hurovits did not like management and why Maraton sold most of their holdings... its a big lesson to learen.....
I am sorry about all that. I hope things do turn around. Even though I am out, I am rooting for them.
The Galilee could use a successful billion-dollar bio company putting bread and butter on many family tables. Iscar alone is not enough for the economy of that area. Imagine the employment opportunities for people living in places such as Acco (Accre), Tzfat (Safed), Nazareth, Sachnin, Rama, and so on...
What I am trying to say is, I am rooting for the company, but for reasons infinitely more important than the share price. The profit made by the investors would be just an added bonus.
FDA Approval will lead to big intrest in the Company and may bring many new cooperations- On the approval date he sold shares together with other executives...
BUT, we are waiting.... still waiting.... we are 11 months from approval date- so far nothing.... the money is running out.... executives are been paid top dollars and....
This is good news for the company, and it does have a slight positive effect on the pps.
My comment back in January was about the $20 prediction made by an obviously uninformed/ignorant poster. The Brazil market potential is not three times those of the U.S. and Israel combined.
If I thought a buy-out was imminent, I would buy back. I would also buy back if I thought the EMA fiasco could be reversed. Brazil is not such a major event as those.
Deal might have been signed a couple of years ago between Pfizer and Brazil. They were just waiting for approval. If you recall, Pfizer gets 60%, so it does not make PLX worth billions. Agreement was for Brazil to manufacture drug itself at a plant in Rio De Janiero over 5 years. Deal was worth $750 million over the 5 years which is about how much Brazil pays for Cerezyme.
Anyway, maybe Brazil and Israel can help turn a profit. Maybe with Brazil drug approval Pfizer might consider the takeover.